It is clearly necessary to prospectively evaluate whether a change in the FABP4 value by direct inhibition, neutralization and/or blockade of unidentified receptors indeed reflects conditions of metabolic syndrome and atherosclerosis and predicts long-term cardiovascular outcomes in the future. This evidence concerns the gene FABP4 and atherosclerosis.